Analyst Charles Rhyee from TD Cowen reiterated a Buy rating on Evolent Health and keeping the price target at $14.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Charles Rhyee has given his Buy rating due to a combination of factors, including Evolent Health’s strong financial performance and optimistic future outlook. The company exceeded its second-quarter estimates for 2025 and subsequently raised its adjusted EBITDA guidance to a range of $140 million to $165 million.
Rhyee’s estimates for 2025 now project an adjusted EBITDA of $161 million and revenue of $1.87 billion, while for 2026, he anticipates an adjusted EBITDA of $196 million and revenue of $2.35 billion. These projections include the revised scope and start date for Evolent Health’s partnership contract with Aetna. Rhyee remains positive about Evolent Health’s prospects, noting that the company’s performance in the first half of the year indicates a turnaround, with strong demand for its solutions in the current market.
In another report released on August 8, KeyBanc also maintained a Buy rating on the stock with a $20.00 price target.